Type I signal peptidases are potential targets for the development of new antibacterial agents. Here we report finding potent inhibitors of E. coli type I signal peptidase (LepB), by optimizing a previously reported hit compound, decanoyl-PTANA-CHO, through modifications at the N-and C-termini. Good improvements of inhibitory potency were obtained, with IC 50 s in the low nanomolar range. The best inhibitors also showed good antimicrobial activity, with MICs in the low lg/mL range for several bacterial species. The selection of resistant mutants provided strong support for LepB as the target of these compounds. The cytotoxicity and hemolytic profiles of these compounds are not optimal but the finding that minor structural changes cause the large effects on these properties suggests that there is potential for optimization in future studies.
Introduction
The frequency of antimicrobial resistance has increased significantly in recent decades. 1, 2 There is an urgent need to discover and develop new drugs with novel modes of action that are effective against drug-resistant strains. 1 Of particular interest from the clinical perspective are the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) that cause the majority of healthcare-associated infections worldwide. 3 In recent decades, type I signal peptidases (SPase I) have been extensively explored as potential targets for new antibacterial agents. Signal peptidases play a crucial role in the bacterial Sec and Tat secretion pathways, catalyzing the cleavage of a largely hydrophobic N-terminal sequence (the signal or ''leader" peptide) from their natural substrates (which include most pre-secretory proteins). 4 Inhibition of SPase leads to an accumulation of pre-proteins at the phospholipid bilayer and cell death. 5, 6 Bacterial SPases are essential enzymes 6, 7 that differ significantly from their eukaryotic counterparts, 8 making these enzymes attractive targets for drug development. SPases I (EC 3.4.21.89) are endopeptidases that belong to the serine protease family. They are ubiquitous and well conserved among bacterial species. The biochemical properties of SPases I from Gram-positive bacteria (B. subtilis, S. pneumoniae, 9 and S. 50 , half maximal inhibitory concentration; MIC, minimal inhibitory concentration; SPPS, solid-phase peptide synthesis; TES, triethylsilane; SPase I, type I signal peptidase; TFA, trifluoroacetic acid. studied in detail. SPase I of E. coli, commonly known as LepB, and herein designated EcLepB, is the best characterized. 11 SPase I enzymes operate via a Ser/Lys catalytic dyad, which differs from the classical Ser-His-Asp triad seen in most serine proteases. The active site (including S91 and K146 in EcLepB) 12 is located at the outer surface of the cytoplasmic membrane, making it accessible to any inhibitor able to cross the outer membrane of Gram-negatives, or the cell wall of Gram-positives. 11, 13 SPases have evolved recognition criteria consistent with their need to cleave many, but not all, peptide sequences. The canonical signal peptide starts with a short positively-charged region, followed by a hydrophobic segment of sufficient length to span the membrane in question in a presumably a-helical conformation, then the actual recognition sequence characterized by small, neutral residues in the À3 (P3) and À1 (P1) positions relative to the point of cleavage, the so-called Ala-X-Ala sequence. The fact that the substrates are pre-oriented, by virtue of the placement of their hydrophobic segment in the lipid bilayer, is thought to be a factor of importance for activity. 12 To date, the search for effective drugs has uncovered three classes of SPase I inhibitors, namely penems (b-lactams), 14, 15 arylomycins 16, 17 and oligopeptides 18 ( Fig. 1) . However, useful therapies targeting these enzymes have not yet been developed. Our group is actively involved in the search for new starting points for antibiotic development, and targeting the LepB enzyme has been one of our areas of interest. A core premise in our work is the STOP (Same-Target-Other-Pathogen) strategy, in which one or more enzymes from different species are used to guide chemistry efforts, generating compounds that are then tested against a number of different pathogens. In this way, the benefits of organic synthesis efforts are maximized. In the current study, we aimed at optimizing the structure of the known oligopeptide decanoyl-PTANA-CHO 9 (Fig. 1 , EcLepB IC 50 = 13.4 lM, E. coli MIC > 500 lg/ mL), 18 in order to determine whether we could improve potency against both the enzyme and bacterial cells.
In particular, we wished to investigate the influence of modifications at the N-and C-termini, while keeping the Pro-Thr-Ala-Asn-Ala (PTANA) peptide sequence unchanged. This type of inhibitor was first reported by Bruton et al., and was based on the consensus sequence of pre-proteins in S. aureus. 19 In our studies, the aldehyde warhead at the C-terminus was first replaced with chemically more stable but equally reactive bioisosters such as a-keto-amides, boronic acid and ester (Fig. 2) . We also introduced a proline at P1 0 , which has been shown to convert serine protease substrates into inhibitors. 20, 21 Finally, an analogue simply carrying the unmodified alanine was prepared to determine whether the electrophile moiety at the C-terminus is really required for antibacterial activity. At the N-terminus, the decanoyl tail was replaced with a bulkier 4-(4-hexylphenyl)benzoyl group. A few examples of derivatives without the fatty acid tail, but capped at the N-terminus with an acetyl group, were also prepared, to evaluate the effects on the activity profile. In addition, a positive charge was introduced at the P5 residue in an attempt to increase cell wall permeability 22 and to improve the potency of the compound inside the bacterial cell. Herein, we describe the design, synthesis and in vitro evaluation of these new oligopeptides against EcLepB. Other aspects, such as activity towards a panel of Gramnegative bacteria, cytotoxicity and hemolysis, are also explored.
Results and discussion

Chemistry
The peptides 20, 21a-c, 22, 23 were synthesized by manual solid-phase peptide synthesis (SPPS) from 2-chlorotritylchloride polymer resin 11 (Scheme 1, see Supplementary data for details). Standard 9-fluorenylmethoxycarbonyl amino-protected amino acids (Fmoc-aa-OH) were used, and the protecting group was removed by treatment with 20% piperidine in N,N-dimethylformamide (DMF). Coupling of the appropriate amino acid was performed in DMF using N,N,N 0 ,N 0 -tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) as the coupling reagent, in the presence of N,N-diisopropylethylamine (DIEA) as the base, and shaking at room temperature for 2 h. When a-branched amino acids (e.g. Fmoc-O-tert-butyl-l-threonine) or secondary amines (Fmoc-l-proline) were involved, longer reaction times were preferred (14 h) or a double coupling was performed (2 h + 2 h, treating the resin with a fresh solution of reagents). After each round of coupling and deprotection steps, the resin was extensively washed with DMF, methanol and dichloromethane, then dried under high vacuum.
Coupling of the tail at the N-terminus, using acetic anhydride, decanoic anhydride and 4 0 -hexyl-biphenyl-carboxylic acid, respectively, afforded intermediates 17a-c, 18 . In the case of the modified proline 16, the fatty acid tail was directly coupled to the commercially available 4-hydroxyproline 26 (Scheme 2).
Next, cleavage of resin-bound peptides 13, 17a-c, 18 and 19 by treatment with a solution of 1,1,1,3,3,3-hexafluoro-2-propanol: dichloromethane (1:4), 23 afforded peptides 20, 21a-c, 22 and 23.
Scheme 2 depicts the synthesis of the modified proline 16. Starting from 4-hydroxyproline methyl ester hydrochloric salt 26, selective coupling of 4 0 -hexyl-biphenyl carboxylic acid 24 at the nitrogen was achieved in high yield, via generation of the corresponding chloride 25. The hydroxyl group was converted into a better leaving group via tosylation and subsequent cyanation of intermediate 28 gave compound 29 as a mixture of two diastereomers in 55% yield. Reduction of the nitrile, using a mixture of platinum oxide and palladium on carbon in acidic medium at room temperature under hydrogen atmosphere, afforded the chloride salt 30, which was protected in high yield using di-tert-butyl dicarbonate in the presence of triethylamine. Finally, treatment of the salt precursor 31 with lithium hydroxide in a mixture of methanol-THF-water (1:1:1) afforded the desired modified proline 16. The synthesis of the modified alanine carrying the warheads is shown in Scheme 3.
First, the Weinreb amide 34 was prepared by coupling the commercially available N-tert-butoxycarbonyl-l-alanine 32 with N,Odimethylhydroxyamine 24 33, and then reduced to the corresponding aldehyde 35 by treatment with lithium aluminum hydride at À15°C (Scheme 3-I). Reaction of the aldehyde 35 with the appropriate isonitrile 38a-b in the presence of acetic acid (functioning both as the catalyst and as the protecting group of the newly formed secondary alcohol) at À78°C, afforded the a-protected alcohols 39a-b in 40-84% yields. Isonitrile 38a was prepared by microwave heating of a mixture of naphthylmethylamine 36 and ethylformate 37 at 130°C for 30 min. The obtained formamide was dissolved in anhydrous THF and phosphorous oxychloride was slowly added at À78°C, stirring at room temperature over- night. Deprotection of the obtained secondary alcohols 39a-b by treatment with potassium carbonate and subsequent PfitznerMoffatt oxidation gave precursors 40a-b in 25-63% yields.
Removal of the tert-butoxycarbonyl protecting group in acidic medium afforded the final a-keto-amide hydrochloric salts 41a-b in quantitative yields. The P1 0 proline analogue 45 was prepared as described in Scheme 3-II. Coupling of commercially available N-methylpyrrolidine-2-carboxamide 43 with Fmoc-l-alanine 42 gave the dipeptide 44, which was treated with 30% piperidine in ethanol to remove the Fmoc protecting group, yielding the desired product 45. Further, the a-naphthylmethyl keto-amide 41b and commercial (R)-boroAla-(+)-pinanediol hydrochloride 47 were capped at the nitrogen with an acetyl group by treatment with acetic anhydride, yielding compounds 46 and 48, respectively (Scheme 3-III).
The obtained peptides 20, 21a-c, 22 and 23 were coupled at the C-terminus with the modified alanine carrying the warheads 41a-b, 45, 47 and 49. Finally, deprotection of the side chains by using aq. 95% trifluoroacetic acid or a mixture of dichloromethane:trifluoroacetic acid:triethylsilane (10:9:1) afforded the final oligopeptides 50a-p (Scheme 4). ; these values compare favorably with the reported activity of the S. pneumoniae SPase I on the same substrate (k cat 0.032 s
À1
, K m 1.18 Â 10 À4 ). 25 The values for both substrates are in good agreement with earlier results for EcLepB. 12 For further assay work, we decided to use the antigen 85A-based sequence.
As documented in the Supplementary data, cleavage of labeled and unlabeled substrates was investigated using mass spectrometry. In each case, intact substrate could be detected, and was shown to decrease with time. Products were identified corresponding to the C-terminal fragments predicted by SignalP, 26 but not the N-terminal fragments (perhaps reflecting additional degradation of the latter).
Evaluation of EcLepB IC 50 and MIC
All newly synthesized oligopeptides 50a-p were evaluated for their inhibitory activity against the EcLepB enzyme, and antibacterial activity against a panel of strains; the results are reported in Tables 1 and 2. Table 1 shows the percentage inhibition for the reference compound 9, and for the new compounds with less than 50% inhibition when tested at 100 lM. Table 2 presents the IC 50 values (and MIC) for compounds that had more than 50% inhibition of enzyme activity at 100 lM (% inhibition data not shown).
As seen in Table 1 , our first compounds (50a-i) were very poor inhibitors of the enzyme. As expected, the analogue 50a, missing the warhead at the C-terminus, was almost completely inactive at a concentration of 100 lM (EcLepB percentage of inhibition < 50%), indicating that a reactive electrophilic moiety at this position promotes inhibition. Our initial idea for optimization of the PTANA hit was to replace the aldehyde warhead of inhibitor 9 at the C-terminus with a chemically more stable but equally reactive group, while keeping the decanoyl tail at the N-terminus unchanged. We hypothesized that, similar to the 5S-penem type of inhibitors, an electrophilic and highly reactive warhead could covalently bind S91 in the active site of LepB. 27 Following the classical approach of inhibiting serine protease enzymes with a-ketoamides, 28 two moieties were chosen, namely tert-butyl-(50b) and a-naphthylmethyl-keto-amides (50c). Surprisingly, the inhibitory activity was severely compromised (compare 50b-c to inhibitor 9). We introduced a proline in the P1 0 position, which has previously produced effective inhibitors, 20 but this was likewise not a viable approach (50d). Removal of the fatty acid tail (50e-g) and/or truncation of the peptide PTANA sequence (50h-i) also produced rather inactive compounds. Next, based on recent findings in the patent literature, 29, 30 we introduced a boronic ester and/or acid warhead at the C-terminus. Gratifyingly, a very good inhibitor 50j was obtained, 25-fold more potent than the reference inhibitor 9 (IC 50 = 48 vs 1200 nM, see Table 2 ), that could serve as a lead for further SAR studies. To start, the alkyl tail at the N-terminus was replaced with a bulkier aromatic fatty acid group; the 4 0 -hexylbiphenyl moiety was chosen, as it has been shown to improve antimicrobial activity of the arylomycin series against a panel of microorganisms. 31 The resulting inhibitor 50k (IC 50 = 12 nM) was 4-fold more potent than the parent 50j. Surprisingly, 29,30 the hydrolyzed analogue 50l having a boronic acid warhead showed lower potency (IC 50 = 230 nM) than the corresponding boronic ester derivative 50k. From these data, it was clear that modifications of the warhead and tail both contributed to the significant increase in potency of the new inhibitors compared to 9. According to the literature, 32,33 the fatty acid tail in the arylomycin series is positioned close to the enzyme-membrane association surface, and the backbone is tightly bound via a hydrogen-bonding network. Consistent with this, replacement of the aromatic fatty acid tail with an acetyl moiety (50o) or removal of the entire fatty acid tail (50p) resulted in a large decrease in inhibitory activity (IC 50 = 26,000 nM). When the warheads alone (in the N-acylated form, 46 and 48) were tested in the same assay, inhibition was also very poor ( Table 1 ). The active lipopeptides were then evaluated against a panel of Gram-negative bacteria, as well as one Grampositive organism, S. aureus (Table 2 ). Compound 9 lacked antibacterial activity completely. Despite their low IC 50 values, inhibitors 50j-l did not show useful activity against the Gram-negatives but some activity could be seen against S. aureus. We decided to introduce a positive charge at the P5 proline residue of the lipopeptides (compounds 50m and 50n), hoping to increase uptake and thereby the antimicrobial potency. Our docking study of inhibitor 50n into EcLepB 34 ( Fig. 3) , indicated that this group should fit nicely into the enzyme active site. For the modeling, the fatty acid tail of 50n was truncated to acetyl, as the enzyme lacks strong determinants for orienting the tail. As seen in Fig. 3 , the P2, P4, and P5 side chains are exposed to bulk solvent and should tolerate structural variations without loss of target affinity. A positivelycharged side chain at P5 could potentially interact with either E83 or D143. The two new inhibitors, 50m-n, blocked the growth of most of the bacteria tested, and were much more potent in this regard than the reference inhibitor 9. It should be noted that these two inhibitors have both a bulky aromatic fatty acid tail, a key element for Table 1 Compounds showing less than 50% inhibition of EcLepB, when tested at a concentration of 100 lM. Table 2 . Table 2 Further characterization of compounds where in vitro inhibition was at least 50% in tests at 100 lM. good affinity, and a cationic group added to the proline at P5, which is apparently required for permeability. It was comforting to see that introduction of a positive charge at the proline did not compromise the inhibitory activity. In fact, compounds 50m-n were among the most potent EcLepB inhibitors we obtained, with IC 50 values of 18 and 6 nM, respectively. The minor difference in the IC 50 values of the two compounds could potentially indicate hydrolysis of the ester into the corresponding acid, although in the active site of EcLepB, there is space between residues S91 and K146 to accommodate a bulky ester (see Fig. 3 ). Indeed, hydrolysis could potentially be catalyzed by the enzyme in a similar manner to that for the natural substrates. However, we note that the observed reaction rates were linear over the 2 h time course of the kinetics experiment, and so if such hydrolysis is occurring, it must be rapid (during the 10-min pre-incubation step). In this case, the boronic ester derivative appeared to be more potent than the boronic acid, in contrast to the 50k-l result described above.
Evaluation of cytotoxicity and hemolysis
Inhibitors 50j-p were also evaluated on the HepG2 cell line 36 for cytotoxicity (for details see Supplementary data), and most were evaluated in a hemolysis assay; the results are reported in fairly well in the hemolysis assay. These compounds, in principle, lack activity against Gram-negative organisms, although results with S. aureus were more promising. Inhibitors 50m and 50n only differ in the warhead, having either a boronic ester or boronic acid group. They also have good EcLepB IC 50 s (18 and 6 nM, respectively), although they gave poor results in both cytotoxicity and hemolysis assays. The introduction of a positive charge at P5 of these two compounds appears to be correlated with the fact that they are active on most of the bacterial strains evaluated. However, these compounds effects on other properties do not follow any clear pattern. In the case of the 50k/50m pair, the introduction of the positively charged group is associated with less cytotoxicity, but more hemolysis; inhibition of the enzyme is not changed significantly. In the case of the 50l/50n pair, inhibition of the enzyme is better, while cytotoxicity and hemolysis are increased.
Profiling of LepB inhibitor from the patent literature
Finally, we synthesized one of the inhibitors from the WO 2015/023898 patent application to include it in our work as a reference compound. We selected compound 50q, one of the more potent compounds based on the reported EcLepB IC 50 and E. coli MIC values, and which, furthermore, could be easily synthesized. Compound 50q is similar to our inhibitors (presented in Table 2 ) in structure and activity profile. The synthesis was performed according to the methods described in the patent, and the characterization of compound 50q is detailed in the Supplementary data. The most similar compound in our series 50m is 6-fold more potent (EcLepB IC 50 18 nM) than the reference compound 50q (EcLepB IC 50 110 nM). However, 50q has a slightly better MIC on wild-type strains of E. coli and K. pneumonia (Table 2) . Compound 50q bears two positive charges as compared to one positive charge in the analogue 50m, which may explain its higher hemolytic activity.
Selection of resistant mutants
The spontaneous frequency of resistance, measured by plating efflux-deficient DtolC E. coli at 8 Â MIC, was <5 Â 10 À8 for 50m, À9 for 50q. Resistant mutants for whole genome sequencing were raised against both 50m and 50q by serial passage of E. coli MG1655 DtolC at successively increasing concentrations of each compound (Supplemental material). In each case the great majority of the mutants (8/10 for 50m, 11/11 for 50q) had acquired mutations in lepB causing amino acid substitutions (Tables S3 and S4 ). The clustered location of most of the mutations in the structure of LepB (Glu83, Phe85, Ile87, Pro88, and Ile145) supports the hypothesis that these inhibitors bind in the active site of the enzyme (Fig. 3) . The different mutations in LepB had similar effects on susceptibility, increasing MIC from 1-2 lg/mL up to 8-16 lg/mL (Tables S3, S4 ). The precise mechanism by which the LepB mutations cause resistance has not been investigated but the nature of these binding-pocket mutations is consistent with them acting to reduce compound affinity for LepB, and so supports inhibition of LepB function as the whole cell mode of action of compounds 50m and 50q. Several mutants carried a second mutation in LepB at either Ala6 (50m) or Asp113 (50q). The significance of these second mutations is not clear but the increase in MIC associated with mutants carrying only single amino acid substitutions shows that a single substitution in the binding pocket is sufficient to fully account for the increase in MIC (Fig. 3, Tables S3, S4 ). Several mutants also carried 1 or 2 mutations in additional genes (Tables S3, S4 ). The significance of these additional mutations is unclear, but as 12 of 19 mutants carried only LepB mutations, we can be confident that mutation in LepB is sufficient to confer the resistant phenotype.
Conclusions
The rapid development of antimicrobial resistance represents one of the major challenges in the search for new antibiotics. Type I signal peptidases (SPases I) are for a number of reasons attractive targets for the development of antibacterial agents with a novel mode of action. In this study, we explored the possibility of finding potent EcLepB inhibitors by optimizing the existing hit compound 9. A set of 16 oligopeptides 50a-p structurally related to the decanoyl-PTANA-CHO inhibitor 9 were designed, synthesized and evaluated. In general, good improvement of inhibitory potency was obtained. Four inhibitors (50j, 50k, 50m and 50n) were found to be very active, showing IC 50 s in the low nanomolar range. In particular, inhibitor 50n was the most potent of this new series of oligopeptides (IC 50 = 6 nM). Two of the best inhibitors (50m-n) also showed promising antimicrobial activity, with MICs in the low lg/mL range for several strains. The results obtained showed that a bulky fatty acid tail at the N-terminus, an electrophilic and highly-reactive warhead at the C-terminus, and a positively charged proline in the P5 position, are key features for obtaining good inhibitors that can be used as potential starting points for antibiotic drug discovery. Raising mutants based on 50m and 50q and performing whole genome sequencing of these enabled us to confirm the mode of action of the synthesized inhibitors. Out of 21 mutants, 19 carried mutations in LepB (12 had no additional mutations in any other genes), which lends strong support to the premise that LepB is the target for our inhibitors. Although it is also clear that more optimization will be required to obtain inhibitors with favorable cytotoxicity and hemolytic profiles, we showed that minor changes in the oligopeptides often produce large effects in their biological profile and this information can be exploited in future studies.
Experimental section
General methods
Analytical thin layer chromatography (TLC) was performed using Merck aluminum sheets precoated with silica gel 60 F 254 . Column chromatography was performed on Merck silica gel 60 Fig. 3 . Molecular modeling of a covalently bound N-acetyl analogue of 50n (both diastereomers) into EcLepB (PDB code: 3IIQ), 35 illustrating the direction of the hydrophobic tail towards the membrane association surface. Boronic esters fit between S91 and K146, and the amine at P5 is in contact with E83 on the surface of the enzyme (the numbering system for the protein has been adjusted to reflect the corrected sequence reported by Paetzel et al.). 12 Mutations in amino acids in resistant strains from 50m are numbered in red (vide infra). SiteMap-calculated volumes shown in yellow highlight the two hydrophobic regions contributing to the recognition of the Ala-X-Ala motif. To a solution of the peptide (1 eq.) in anhydrous DMF (2 or 5 mL) or anhydrous DCM (3 mL) HBTU or HATU or EDCI (1.2 or 2 eq.) and DIEA (3 or 6 eq.) were added under N 2 flow and the mixture was stirred at room temperature or 0°C for 10 min, after which the warhead (2 or 3 eq.) was added and the reaction mixture was stirred at room temperature till completion (monitoring via RPLC-MS). The solvent was evaporated under N 2 stream and the residue was used for the next step (deprotection or oxidation) without or after purification by RP-HPLC.
General method for the side chain deprotection
The crude or pure protected peptides were dissolved in a solution of 95% TFA in H 2 O or in a solution of TFA:DCM:TES (10:9:1) and stirred at room temperature till completion (generally 1 or 2 h). The solvents were removed under reduced pressure and the residues were purified by preparative RP-HPLC.
The analogue was prepared according to the general procedure using peptide 21b (0.022 mmol, 0.019 g), alanine (l-Ala-OH) 49 (0.044 mmol, 0.004 g) in anhydrous DMF (2 mL), in the presence of HBTU (0.044 mmol, 0.016 g) and DIEA (0.11 mmol, 0.014 g). The crude material was used directly for the deprotection step, after which preparative RP-HPLC purification was performed. 3.5 mg (25%, over 2 steps) of desired oligopeptide 50a as a white solid were obtained. 1 
(S)-N 1 -((S)-4-(tert-Butylamino)-3,4-dioxobutan-2-yl)-2-((S)-2-((2S,3S)-2-((S)-1-decanoylpyrrolidine-2-carboxamido)-3-hydroxybutanamido)propanamido)succinamide (50b)
The analogue was prepared according to the general procedure using the peptide 21b (0.023 mmol, 0.020 g), the modified alanine 41a (0.046 mmol, 0.008 g) in anhydrous DMF (2 mL), in the presence of HBTU (0.046 mmol, 0.017 g) and DIEA (0.115 mmol, 0.015 g). The crude material was purified by preparative RP-HPLC, to get 9.5 mg (41%, MS (ESI) m/z 1008. 8 
(S)-2-((S)-2-((2S,3S)-2-((S)-
The analogue was prepared according to the general procedure using the peptide 21b (0.024 mmol, 0.021 g), the modified alanine 41b (0.048 mmol, 0.012 g) in anhydrous DMF (2 mL 
The analogue was prepared according to the general procedure using the peptide 21b (0.031 mmol, 0.026 g), and the modified proline 45 (0.037 mmol, 0.007 g) in anhydrous DCM (3 mL), in the presence of HBTU (0.037 mmol, 0.014 g) and DIEA (0.074 mmol, 0.009 g). Deprotection of the side chains was carried out according to the general procedure (95% TFA in H 2 O, 2 mL) after which the solvents were evaporated and the residue (yellow oil) was purified by preparative RP-HPLC, affording 0.014 g (62%, over two steps) of desired oligopeptide 50d as a white solid. 
(S)-2-((S)-2-((2S,3S)-2-((S
The analogue was prepared according to the general procedure using the peptide 21a (0.033 mmol, 0.025 g), and the warhead 41a . Deprotection of the side chains was carried out according to the general procedure (95% TFA in H 2 O, 2 mL) after which the solvents were evaporated and the residue (yellow oil) was purified by preparative RP-HPLC, affording 5 mg (43%) of desired oligopeptide 50f as a white solid. 
(S)-2-((S)-2-((2S,3S)-2-((S)-
The analogue was prepared according to the general procedure using the peptide 21a (0.027 mmol, 0.020 g), and the modified proline 45 (0.027 mmol, 0.005 g) in anhydrous DCM (3 mL) in the presence of HBTU (0.027 mmol, 0.011 g) and DIEA (0.054 mmol, 0.007 g). Deprotection of the side chains was carried out according to the general procedure (95% TFA in H 2 O, 2 mL) after which the solvents were evaporated and the residue (yellow oil) was purified by preparative RP-HPLC, affording 3 mg (18%, over two steps) of desired oligopeptide 50g as a white solid. RP-HPLC purity: C18 column > 95%. C 27 
(S)-2-((S)-2-Acetamidopropanamido
The analogue was prepared according to the general procedure using the peptide 22 (0.051 mmol, 0.025 g), and the warhead 41a (0.153 mmol, 0.032 g) in anhydrous DMF (3 mL) in the presence of HBTU (0.153 mmol, 0.058 g) and DIEA (0.306 mmol, 0.039 g). The crude material was purified by RP-HPLC affording 0.013 g (40%) of pure protected oligopeptide as a fluffy white solid. + . Deprotection of the side chains was carried out according to the general procedure (95% TFA in H 2 O, 2 mL) after which the solvents were evaporated and the residue (yellow oil) was purified by preparative RP-HPLC, affording 5 mg (62%) of desired oligopeptide 50h as a white solid. 
The analogue was prepared according to the general procedure using the peptide 22 (0.051 mmol, 0.025 g), and the warhead 41b (0.153 mmol, 0.045 g) in anhydrous DMF (3 mL) in the presence of HBTU (0.153 mmol, 0.058 g) and DIEA (0.306 mmol, 0.039 g). The crude material was purified by RP-HPLC affording 0.018 g (49%) of pure compound as a fluffy white solid. C 43 
(S)-2-((S)-2-((2S,3S)-2-((S
The analogue was prepared according to the general procedure using the peptide 21b (0.064 mmol, 0.055 g), and the warhead (R)-BoroAla-(+)-Pinanediol hydrochloride 47 (0.128 mmol, 0.033 g) in anhydrous DCM (3 mL) in the presence of EDCI (0.128 mmol, 0.020 g) and DIEA (0.192 mmol, 0.025 g). DCM was evaporated and deprotection of the side chains was performed according to the general method (TFA:DCM:TES, 10:9:1, 3 mL). The crude yellow oil was purified by preparative RP-HPLC (using TEAA, triethylammonium acetate, as the buffer, to avoid hydrolysis of the boronic ester to boronic acid), affording 0.010 g (20%, over two steps) of desired oligopeptide 50j as a white solid. The 
(S)-2-((S)-2-((2S,3S)-2-((
The analogue was prepared according to the general procedure using the peptide 21c (0.026 mmol, 0.025 g), and the warhead (R)-BoroAla-(+)-Pinanediol hydrochloride 47 (0.052 mmol, 0.013 g) in anhydrous DCM (3 mL) in the presence of EDCI (0.052 mmol, 0.008 g) and DIEA (0.126 mmol, 0.020 g). DCM was evaporated and deprotection of the side chains was performed according to the general method (TFA:DCM:TES, 10:9:1, 3 mL). The crude yellow oil was purified by preparative RP-HPLC (using TEAA as the buffer), affording 6 mg (27%, over two steps) of desired oligopeptide ester 50k. A small fraction (2.4 mg, 13%) of boronic acid 50l was also isolated. 
((3S,6S,9S,12R)-
9-(2-Amino-2-oxoethyl)-1-((S)-1-(4 0 -hexyl- [1,1 0 -biphenyl]-4-carbonyl)pyrrolidin-2-yl)-3-((S)-1-hydroxyethyl)-6- methyl-1,
(2S)-2-((2S)-2-((2S,3S)-2-((2S)-4-
The analogue was prepared according to the general procedure using the peptide 23 (0.050 mmol, 0.056 g), and the warhead (R)-BoroAla-(+)-Pinanediol hydrochloride 47 (0.100 mmol, 0.026 g) in anhydrous DCM (5 mL), in the presence of HATU (0.100 mmol, 0.038 g) and DIEA (0.15 mmol, 0.020 g). DCM was evaporated and deprotection of the side chains was performed according to the general method (TFA:DCM:TES, 10:9:1, 3 mL). The crude yellow oil was purified by preparative RP-HPLC (using TEAA, as the buffer), affording 6 mg (21%, over two steps) of desired oligopeptide ester 50m. A small fraction (2.2 mg, 6.3%) of boronic acid 50n was also isolated, along with a second fraction of the de-boronation by-product 50o. 
((3S,6S,9S,12R)-
9-(2-amino-2-oxoethyl)-1-((2S)-4-(aminom- ethyl)-1-(4 0 -hexyl-[1,1 0 -biphenyl]-4-carbonyl)pyrrolidin-2-yl)-3-((S)- 1-hydroxyethyl)-6-methyl-1,
(S)-2-((S)-2-((2S
The analogue was prepared according to the general procedure using the peptide 21a (0.054 mmol, 0.040 g), and the warhead (R)-BoroAla-(+)-Pinanediol hydrochloride 47 (0.108 mmol, 0.028 g) in anhydrous DCM (3 mL) in the presence of HATU (0.108 mmol, 0.041 g) and DIEA (0.162 mmol, 0.021 g). DCM was evaporated and deprotection of the side chains was performed according to the general method (TFA:DCM:TES, 10:9:1, 2 mL). The crude yellow oil was purified by preparative RP-HPLC (using TEAA as the buffer), affording 5 mg (14%, over two steps) of desired oligopeptide ester 50o. 
Computational details
All calculations were performed using the Schrödinger Small Molecule Drug Discovery Suite (Schrödinger Release 2015-4) using the OPLS-2005 force field. 37 The E. coli crystal structure 3IIQ 35 was downloaded from the PDB and prepared using Protein Preparation Wizard. 38 This implied the addition of hydrogens, the assignment of protonation states and optimization of the hydrogen bond network followed by a restrained minimization. To model the binding of both diastereomers of the N-acetyl analogue of 50n, these ligands were built manually into the active site of LepB, using the protein bound conformation of arylomycin as a template. A (R)-boroalanine was added to the C-terminal and the boron was attached covalently to Ser91. The resulting complexes were further refined by 1000 steps of conformational sampling by MCMM using the GB/SA continuum solvation model for water 39 in the optimization step. Torsion angles sampled were those of the ligand and protein side chains in close contact with the ligand. The backbone of the protein as well as amino acids more than 5 Å away from the ligand were kept fixed. SiteMap 40 was used to identify and visual-ize the hydrophobic patches responsible for the Ala-X-Ala recognition.
Production of EcLepB
Details of EcLepB cloning, expression and purification are provided in the Supplementary data. Briefly, a full-length construct was designed that included a His 6 tag between the two transmembrane helices predicted at the N-terminal end, replacing residues known to represent a self-cleavage site in the wild type sequence. 34 The resulting protein was expressed at high levels in E. coli, extracted from the membrane fraction with 1% reduced Triton X-100, then purified by metal-chelation chromatography with good yield in the presence of 0.5% detergent.
Assay
EcLepB activity and inhibition were determined using a FRET-pair assay, as detailed in the Supplementary data. Dabcyl-VGGTATA;GAFSRPGLE(EDANS)-OH, and dabcyl-KLTFGTVKPVQAIA; GYEILE(EDANS)-OH were used as substrates, where dabcyl was the fluorescence acceptor and EDANS was the fluorescence donor; the expected cleavage sites are indicated with arrows. The linear increase in fluorescence, corresponding to substrate cleavage, was monitored at 22°C for 2 h. For inhibition tests, EcLepB was pre-incubated with the compound for 10 min at 22°C, then the reaction was followed at a substrate (dabcyl-VGGTATAGAFSRP-GLE(EDANS)-OH) concentration of 8 lM; final EcLepB concentration was estimated to be 50 nM. Reaction rates were plotted as a function of inhibitor concentration, and half maximal inhibitory concentration (IC 50 ) values were determined by a non-linear regression analysis of the sigmoidal dose-response curves in GraphPad Prism (GraphPad software Inc., CA, USA).
Substrate cleavage sites
Cleavage sites were investigated for two substrates (one unlabeled peptide VGGTATAGAFSRPGL, as well as the dabcyl-VGGTA-TAGAFSRPGLE(EDANS)-OH substrate) by mass spectrometry (MS), as described in the Supplementary data. Briefly, a 5 fmol sample of each intact substrate was loaded to the LC-MS for initial characterization. Subsequently, 10 lL of 5 lM substrate was incubated with 2.3 lM EcLepB. Samples (1 lL) were taken at 1, 2, 3, 4 and 5 h, as well as overnight; each sample was diluted 1000 times with 0.25% acetic acid, then loaded to the LC-MS to identify the products, both qualitatively and quantitatively. The samples from the incubation were analyzed using nanoscale liquid chromatography (nanoAdvance, Bruker Daltonics, Bremen, Germany) coupled to an electrospray ionization quadrupole time-of-flight mass spectrometer (Maxis Impact, Bruker Daltonics). They were injected and desalted on a pre-column (100 lm i.d. Â 20 mm, C18 PepMap100, 5 lm, 100 Å) at a flow-rate of 10 lL/min for 4 min. A fused silica needle emitter (15 cm, 75 lm i.d., 375 lm o.d., Picotip, New Objective, Woburn, MA, packed with Reprosil-Pur C18-AQ, 3 lm resin) was used as spray emitter and analytical column.
The mobile phases were 0.1% formic acid in water (buffer A) and 0.1% formic acid in acetonitrile (buffer B). Each sample was analyzed during a 20 min gradient (3-50% buffer B) at a flow rate of 300 nL/min at 50°C. Mass spectra were collected in full MS scan mode (m/z 50-2000).
Evaluation of minimum inhibitory concentration (MIC)
Compounds were evaluated against a panel of Gram-negative bacteria, including E. coli (ATCC 25922, wild-type; CH3130, an efflux-defective DtolC mutant isogenic to ATCC 25922; D22, a drug-hypersensitive lpxC mutant), P. aeruginosa (PAO1, wild-type; PAO750, an efflux-defective mutant isogenic to PAO1), K. pneumonia (ATCC 13833, wild-type), A. baumannii (ATCC 19606, wildtype), and the Gram-positive S. aureus (ATCC 29213, wild-type). In vitro antimicrobial activity of each compound was determined by measuring the MIC using the broth micro-dilution technique in cation-adjusted Mueller-Hinton II medium (Becton-Dickinson, 212322) according to EUCAST and CLSI guidelines (for details, see the Supplementary data, 2.2). 41 
Evaluation of cytotoxicity
Compounds were evaluated in a fluorometric microculture cytotoxicity assay (FMCA) and the HepG2 cell line was used for the study (see Supplementary data for more details). 36 Cytotoxicity was assessed after 72 h with cell survival presented as survival index (SI, %) defined as fluorescence in test wells in percent of control cultures with blank values subtracted. The IC 50 was determined from log concentration-effect curves in Graph Pad Prism using a non-linear regression analysis.
Hemolysis studies
Compounds were evaluated for hemolytic activity using red blood cells from heparinized human blood (for details, see the Supplementary data, 2.3).
Selection and sequence identification of resistant E. coli mutants
Mutants of E. coli DtolC resistant to compounds 50m and 50q 29 were isolated by serial passage with selection for growth at increasing concentrations of compound. Mutations were identified by whole genome sequencing of independently selected mutants with increased MIC values (for details, see the Supplementary data, 2.4).
